Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?
Journal
Veterinary Journal
Journal Volume
213
Pages
87-89
Date Issued
2016
Author(s)
Abstract
Combination chemotherapy, using cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP), is the most commonly used treatment for canine lymphoma. Most affected dogs respond during the initial stages of chemotherapy, but many relapse. The aim of this study was to evaluate the relationship between the use of specific chemotherapy drugs and clinical relapse, using the modified Madison-Wisconsin, 25 week chemotherapy protocol. Forty-one of 68 dogs affected with multicentric lymphoma relapsed during the treatment period. Relapse occurred more frequently after the administration of cyclophosphamide (n?=?24; P?
SDGs
Other Subjects
cyclophosphamide; doxorubicin; prednisolone; vincristine; antineoplastic agent; cyclophosphamide; doxorubicin; prednisone; vincristine; Article; cancer combination chemotherapy; controlled study; dog; female; lymphoma; male; nonhuman; retrospective study; Taiwan; tumor recurrence; animal; Dog Diseases; lymphoma; recurrent disease; veterinary; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxorubicin; Female; Lymphoma; Male; Prednisone; Recurrence; Vincristine
Type
journal article